EXCELYA/XENOTHERA
3.5.2021 12:15:09 CEST | Business Wire | Press release
The biotech company XENOTHERA has begun the European clinical trial of its anti-COVID treatment, XAV-19. The Nantes laboratory is the sponsor of the trial, called EUROXAV, which will be carried out by Excelya , a leading European contract research organization (CRO) specializing in clinical research. EUROXAV is a multi-center, double-blind phase III trial that will recruit 722 patients with moderate COVID, hospitalized or monitored remotely. The trial will take place in Greece, Bulgaria, Romania, Spain and Turkey.
The first patient in the trial was recruited on April 28th at Professor Poulakou's center (GR04) in Greece. The cohort of 722 patients will complement the 398 patients in the POLYCOR trial, a trial carried out in 35 French hospitals under the sponsorship of the Nantes University Hospital, which has just closed its recruitment phase with results expected Summer 2021.
"Excelya is very proud to support XENOTHERA in the development of XAV19, which holds great promise in the battle against COVID19. After taking several months to develop the EUROXAV project, the inclusion of this first patient represents an important milestone. We hope to work quickly to make results available and initiate the next steps to benefit patients and caregivers," said Alan Morgan, CEO of Excelya .
“This milestone marks the start of the EUROXAV trial, the results of which are awaited with great interest. The aim of the trial is to evaluate the efficacy of XAV-19 in hospitalized and ambulatory patients, which will allow us to analyze the medical value of XAV-19 in clinical situations where there is currently no satisfactory therapeutic solution.” comments Odile Duvaux, co-founder and president of XENOTHERA.
*********************
About XAV-19:
XENOTHERA's drug candidate XAV-19 is a protective anti-SARS-CoV-2 polyclonal antibody similar to the natural human response
. Based on a unique and patented proprietary technology, it acts through several mechanisms of action, including neutralizing the virus, reducing inflammation and limiting the risk of cytokine storms.
About XENOTHERA:
Founded in 2014, XENOTHERA is a Nantes-based biotech company that develops "glyco-humanized" polyclonal antibodies. Its technological platform is built on a dual expertise in genetics and immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant in transplantation, has been in the clinic since 2019. XENOTHERA has also been developing its treatment for coronavirus infections for several years. XAV-19 is XENOTHERA's treatment for patients at the beginning of hospitalization, it is based on a unique patented antibody production technology, developed and proven for several years by the biotech.
XENOTHERA, a member of the Atlanpole Biotherapies competitiveness cluster, is part of the scientific and medical environment of the Pays de la Loire. The company has been supported since its creation by private investors, by the Pays de la Loire Region and by BPI France. Since its creation, the company has raised more than 23 million euros to finance all of its products.
For more information: www.xenothera.com
Follow XENOTHERA on social networks: LinkedIn
Twitter
About Excelya Group:
Excelya is an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.
For more information, please visit excelya.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005365/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom